Latest Rhinitis Stories

CARY, N.C., May 25 /PRNewswire/ -- Cetero Research, the leading early-stage contract research organization (CRO), announced today that it has more Environmental Exposure Chambers (EECs), or allergy models for recreating environmental conditions than any other CRO. Over the past nine years, Cetero has used these models in more than 40 clinical studies to help its pharmaceutical partners develop novel therapies for a wide range of anti-allergic small molecule drugs, immunotherapies,...

ANTONY, France, April 19, 2010 /PRNewswire-FirstCall/ -- Stallergenes S.A. today announced the first results of a phase III clinical trial (VO61.08) conducted in the USA on its sublingual grass pollen immunotherapy tablet, Oralair(R). This phase III study is the first clinical study in the USA to be conducted by Stallergenes as part of the Oralair(R) clinical development which already encompassed 4 phase III clinical trials conducted in Europe. This development program has so far...

FT. WASHINGTON, Pa., March 19 /PRNewswire/ -- Allergy sufferer and actress Alison Sweeney today joined the makers of the fastest 24-hour over-the-counter (OTC) allergy medicine, ZYRTEC®, for an unusual race to officially welcome the first day of spring and new ZYRTEC® Liquid Gels. The "Race Against Your Allergies," which took place in New York City's Madison Square Park, featured some unusual runners - six, five-foot-tall noses representing some of allergy sufferers' worst symptoms,...

MISSISSAUGA, ON, March 15 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that it has enrolled the first patient in its European Phase 2 clinical trial evaluating WF10 as a treatment for allergic...

BRIDGEWATER, N.J., March 10 /PRNewswire/ -- Sanofi-aventis U.S. today announced the launch of the Clean Sweep campaign to help guide spring cleaning for the estimated 60 million Americans who are affected by nasal allergies. This campaign helps them locate lurking allergens in their homes and improve their allergy management routine. According to a Spring Cleaning Survey of more than one thousand adults, 94 percent of respondents recognized that proper cleaning can help reduce incidences of...

Doctors from Italy are saying that pollen seasons may be longer due to changes in climate patterns, causing an extended period of congestion and sneezing for people with allergies, especially hay fever. Based on a twenty-six-year study, doctors have discovered an increased amount of pollen in the air progressively extending later and later into the year. The study was concentrated in the Bordighera region of Italy between 1981 and 2007. They recorded pollen counts during the allergy season...

AUSTIN, Texas, Feb. 13 /PRNewswire/ -- The beauty of budding plants and bouquet of aromas are sources of satisfaction for many gardeners. For allergy sufferers, though, gardening can be as much a chore as pursuit of passion. Pollen from trees, shrub and grasses can cause an onslaught of allergy symptoms, including sneezing, itchy eyes, congestion and in some cases, an asthma attack. But sensitive people can take a few simple steps to minimize their risk of exposure to bothersome allergens,...

Medication Delivered Under the Tongue May Be Alternative to Allergy Shots PITTSBURGH, Feb. 12 /PRNewswire-USNewswire/ -- An oral allergy treatment administered in drops under the tongue is a safe and effective alternative to injections for adults who are allergic to ragweed pollen, according to a study published today in the Journal of Allergy and Clinical Immunology by allergic disease specialist at Allegheny General Hospital. Widely used in Europe, but not yet approved by the U.S. Food...

OXFORD, England, February 12 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ToleroMune(R) ragweed allergy T-cell vaccine achieved positive results in a recently completed phase II clinical trial. Ragweed allergy is particularly common in America, where it affects approximately 25% of the population. Circassia's latest clinical results follow two earlier successful phase II studies with the company's T-cell vaccine...

Eczema in early childhood may influence behavior and mental health later in life. This is a key finding of a prospective birth cohort study to which scientists of Helmholtz Zentrum München contributed. In cooperation with colleagues of Ludwig-Maximilians-Universität (LMU), Technische Universität München (TUM) and Marien-Hospital in Wesel, North Rhine-Westphalia this study followed 5,991 children who were born between 1995 and 1998. The study has been published in the current issue...